Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859618 | 0.81 | ESR1 (0.38) | MAPTESR1SMN1; SMN2TBXAS1P4HTM | |
| SCHEMBL6497007 | 0.78 | FPR2 (0.35) | GABRA5GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL2137686 | 0.76 | FDPS (0.49) | KDM4EMAPTESR1SMN1; SMN2ARG1 | |
| Hydrochloric Acid SCHEMBL9715312 | 0.74 | FDPS (0.47) | MAPTESR1SMN1; SMN2TBXAS1ARG1 | |
| SCHEMBL27694004 | 0.74 | — | — | |
| SCHEMBL27978839 | 0.73 | SMN1; SMN2 (0.45) | FPR2CYP1A2MAPTESR1SMN1; SMN2 | |
| SCHEMBL29651715 | 0.72 | ARG1 (0.42) | FPR2KDM4EESR1SMN1; SMN2ARG1 | |
| SCHEMBL28120475 | 0.72 | ESR1 (0.41) | FPR2ESR1SMN1; SMN2ARG1CYP2C19 | |
| SCHEMBL15693850 | 0.72 | — | — | |
| SCHEMBL6446028 | 0.71 | KMT2A (0.43) | CYP1A2KDM4EMAPTESR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-104788596-A | Resin material for removing nickel ions in water and preparation and application methods of resin material | GUANGDE HONGXIA TECHNOLOGY DEV CO LTD | 2015-07-22 | — | — | CN | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1467732-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6759426-B2 | RESPIRATORY SYSTREM DISORDERS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISORDERS | PFIZER INC | 2004-07-06 | — | — | US | disclosed |
| WO-2003061653-A9 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LTD (GB) | 2003-12-24 | — | — | WO | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | GABRA5 845/4885GABRB2 937/4885GABRP 250/4885 |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | GABRA5 845/4885GABRB2 937/4885GABRP 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.